Bruker Gains 50.3% in a Year: What's Driving the Rally?
BRKR's rally is fueled by BSI NANO growth, AI-driven metrology demand and gains in preclinical imaging despite tariff pressures.
BRKR - Bruker Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$52.17
DETAILS
HIGH:
$70.00
LOW:
$35.00
MEDIAN:
$51.50
CONSENSUS:
$52.17
DOWNSIDE:
8.81%
Stock News
The Healthcare M&A Wave
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Bruker Corp (BRKR) Stock Up 4.4% and Still Undervalued -- GF Score: 85/100
On June 15, 2026, Bruker Corp (BRKR) shares rose 4.4% to a current price of $56.63. The stock has shown remarkable performance within the past year, with a 48.7
Bruker Corporation (BRKR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Bruker Corporation (BRKR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Bruker Signals Growth Pivot as Semiconductor and Overseas Orders Gain Steam
Bruker NASDAQ: BRKR is seeing stronger order momentum across several end markets, with semiconductor metrology, non-U.S. academic and government customers, and parts of its diagnostics business helping offset continued weakness in U.S. academic funding, a company representative said at a Jefferies healthcare conference.
Bruker (BRKR) Up 37.1% Since Last Earnings Report: Can It Continue?
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock?
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?
Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration-key factors shaping their long-term investor appeal.
Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026
WASHINGTON--(BUSINESS WIRE)---- $BRKR #BRKR--At ASM Microbe 2026, Bruker Corporation's (Nasdaq: BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and innovations across microbial identification, sepsis diagnostics, molecular testing, and NGS workflows, advancing clinical research, and faster, actionable infectious disease diagnostics. During the ASM 2026 meeting, Bruker showcases the expanded clinical capabilities of the MALDI Biotyper® CA System enabled by.
Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry
At ASMS, [url="]Bruker Corporation[/url] (Nasdaq: BRKR) announced the launch of the new timsMRMS system, designed to empower researchers in petroleomics, susta
Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry
SAN DIEGO--(BUSINESS WIRE)---- $BRKR #BRKR--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the new timsMRMS system, designed to empower researchers in petroleomics, sustainable fuels and advanced energy storage. The timsMRMS is an innovative platform that combines Trapped Ion Mobility Spectrometry (TIMS) with extreme-resolution Magnetic Resonance Mass Spectrometry (MRMS), to unravel the complex molecular makeup of challenging fossil fuels and green energy materials. It accomplishes this wit.
Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics -- all to Enabl
At ASMS, [url="]Bruker Corporation[/url] (Nasdaq: BRKR) announced the launch of the unique timsMRMS system, bringing the power of trapped ion mobility separati
Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology
SAN DIEGO--(BUSINESS WIRE)---- $BRKR #BRKR--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the unique timsMRMS system, bringing the power of trapped ion mobility separation to ultra-high-resolution magnetic resonance mass spectrometry (MRMS). A translational oncology research initiative by Prof. Stephan Singer at University Hospital Tübingen enables therapy selection, measuring more than 10,000 proteins in FFPE biopsies to reveal actionable tumor biology when precision genomics is inconclus.
Champalimaud Foundation's Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation announced the commissioning of a novel BioSpec™ 18 Tesla preclinical MRI, the world's highest-field horizontal-bore MRI system, at the Champalimaud Foundation in Lisbon, Portugal. The BioSpec 18T system provides increased spatial resolution and sensitivity, enabling advanced magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI) methods for cancer and neuroscience research, where characterization of tissue micro.
BRKR Stock Up Post Q1 Earnings & Revenue Beat, Margins Down
Bruker beats Q1 earnings and revenue estimates as Europe growth and strong BSI bookings offset margin pressure and softer organic sales.
Bruker Corporation (BRKR) Q1 2026 Earnings Call Transcript
Bruker Corporation (BRKR) Q1 2026 Earnings Call Transcript
Bruker (BRKR) Surpasses Q1 Earnings and Revenue Estimates
Bruker (BRKR) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.47 per share a year ago.
Bruker Reports First Quarter 2026 Financial Results
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three months ended March 31, 2026. Frank H. Laukien, Bruker's President and CEO, commented: “While US academic demand, tariff and currency headwinds still pressured our first quarter results, our Q1 financial performance came in ahead of expectations. We are encouraged that our first quarter BSI segment bookings grew organically at a high single digit percentage, and our BSI book-to-bi.
Bruker Corp (BRKR) Shares Fall 5.4% -- What GF Score of 81 Tells Investors
On April 29, 2026, Bruker Corp (BRKR) shares fell 5.4% to $34.29, continuing a downward trend that has seen a 27.1% decline year-to-date. The stock has traded w
Forget Neuralink: The Real Brain Tech Trade Has 10 Names You’ve Never Heard
The real brain computer interface opportunity isn't in the headlines. These 10 stocks are building the systems that make it possible.
Bruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report first quarter 2026 financial results before market opening on Wednesday, May 6, 2026. The Company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q1 2026 Earnings Webcast” hyperlink in the “Events & Presentations” section. A slide presenta.
Price Targets
Bruker price target raised to $70 from $50 at Guggenheim
$70.00
(was $60.91)
Subbu Nambi
·
Guggenheim
Bruker price target raised to $60 from $53 at Barclays
$60.00
(was $55.11)
UBS
Bruker price target raised to $45 from $40 at Stifel
$45.00
(was $43.73)
Daniel Arias
·
Stifel Nicolaus
Bruker price target raised to $45 from $40 at UBS
$45.00
(was $42.30)
UBS
Bruker price target raised to $53 from $45 at Barclays
$53.00
(was $42.30)
Luke Sergott
·
Barclays
Bruker price target lowered to $35 from $40 at Goldman Sachs
$35.00
(was $37.19)
Evie Koslosky
·
Goldman Sachs
Bruker price target raised to $49 from $43 at UBS
$49.00
(was $36.99)
UBS
Bruker price target lowered to $50 from $55 at Barclays
$50.00
(was $37.51)
Luke Sergott
·
Barclays
Bruker price target lowered to $50 from $55 at Jefferies
$50.00
(was $37.51)
Jefferies
Bruker price target raised to $58 from $53 at Guggenheim
$58.00
(was $49.02)
Guggenheim
Bruker price target raised to $53 from $45 at Guggenheim
$53.00
(was $49.87)
Subbu Nambi
·
Guggenheim
Bruker price target raised to $55 from $48 at Wells Fargo
$55.00
(was $45.12)
Brandon Couillard
·
Wells Fargo
Bruker price target raised to $55 from $45 at Barclays
$55.00
(was $45.12)
Barclays
Wolfe upgrades Bruker to Outperform on 2026 growth
$60.00
(was $47.65)
Wolfe Research
Bruker initiated with a Sell at Goldman Sachs
$40.00
(was $46.00)
Goldman Sachs
Bruker initiated with a Buy at Rothschild & Co Redburn
$60.00
(was $43.39)
Redburn Partners
Bruker price target raised to $43 from $40 at UBS
$43.00
(was $38.71)
UBS
Bruker price target raised to $45 from $40 at Barclays
$45.00
(was $38.71)
Barclays
Bruker price target lowered to $40 from $43 at Barclays
$40.00
(was $34.72)
Barclays
Bruker price target lowered to $40 from $48 at Stifel
$40.00
(was $32.07)
Daniel Arias
·
Stifel Nicolaus